3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Carcinoma, Transitional Cell
3
Recurrence
2
Urinary Bladder Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Eosinophilia
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Bevacizumab
5
Cetuximab
3
palbociclib
2
encorafenib
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
tislelizumab
1
ribociclib
1
repotrectinib
1
olaparib
1
fludarabine
1
durvalumab
1
dostarlimab
1
atezolizumab
1
Tretinoin
1
Stem Cell Transplantation
1
Sirolimus
1
Ramucirumab
1
Radiotherapy
1
Paclitaxel
1
Oxaliplatin
1
Oviposition
1
Melphalan
1
Lutetium-177
1
Lutetium
1
Levoleucovorin
1
Injections
1
Immunotherapy
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Digestive System Neoplasms
×
pemigatinib
×
1 year
×
Clear all
No trials found.